« Back to Record
Citation APA

Cortes, J., O'Shaughnessy, J., Loesch, D., Blum, J. J., Vahdat, L. L., Petrakova, K., Chollet, P., Manikas, A., Diéras, V., Delozier, T., Vladimirov, V., Cardoso, F., Koh, H., Bougnoux, P., Dutcus, C. C., Seegobin, S., Mir, D., Meneses, N., Wanders, J., & Twelves, C. (2011). Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): A phase 3 open-label randomised study. Lancet, 377(9769), 914-923. doi:10.1016/S0140-6736(11)60070-6


Permalink

http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/169290

Cortes, J., O'Shaughnessy, J., Loesch, D., Blum, J. J., Vahdat, L. L., Petrakova, K., Chollet, P., Manikas, A., Diéras, V., Delozier, T., Vladimirov, V., Cardoso, F., Koh, H., Bougnoux, P., Dutcus, C. C., Seegobin, S., Mir, D., Meneses, N., Wanders, J., & Twelves, C. (2011). Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): A phase 3 open-label randomised study. Lancet, 377(9769), 914-923. doi:10.1016/S0140-6736(11)60070-6